Rapid molecular infectious disease testing for Group A Streptococcus
Customize your policy alerts
Sign up for AmeriHealth Caritas Policy CCP.1563 alerts
Get alerted when Policy CCP.1563 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage of rapid molecular (nucleic acid amplification or amplified probe) tests for suspected Group A Streptococcus (strep throat) in symptomatic individuals and applies to AmeriHealth Caritas benefit determinations.
No material clinical or coverage changes in this revision.
Coverage Determinations
Not medically necessary
Coverage determination
Policy does not identify covered indications for these molecular tests.
Rapid molecular infectious disease testing for Group A Streptococcus, including nucleic acid amplification testing and amplified probe testing, is considered investigational/not clinically proven and therefore not medically necessary for members with suspected streptococcal pharyngitis.
Nucleic acid amplification testing and amplified probe testing for Group A Streptococcus are deemed investigational and not medically necessary for members with suspected streptococcal pharyngitis.
Provider Requirements and Recommendations
Coverage stance — rapid molecular tests are not medically necessary
Rapid molecular testing for Group A Streptococcus (including nucleic acid amplification and amplified probe testing) is investigational/not clinically proven and therefore not medically necessary for members with suspected streptococcal pharyngitis; prior authorization does not apply to services deemed not medically necessary under this policy.
Preferred diagnostic workflow — RADT, throat culture, and clinical scoring
Use standard diagnostic approaches: perform rapid antigen detection testing (RADT) and/or throat culture per CDC guidance; consider validated clinical scoring systems to identify patients with low probability of Group A Streptococcus who may not need testing. Symptomatic children older than 3 years with a negative RADT should receive throat culture confirmation.
- RADT provides point-of-care results but has lower sensitivity than molecular testing.
- Throat culture identifies viable organisms but requires incubation time.
- Clinical scoring systems are suggested to determine who should undergo testing and are most useful to rule out testing in low-probability patients.
Coding and documentation — common procedure codes and billing guidance
If billed, the most commonly submitted procedure codes for molecular Group A Streptococcus testing are CPT 87650, 87651, and 87652; CPT 87880 may be used for rapid antigen detection testing and CPT 87081 for throat culture. Providers must consult coding manuals and plan requirements when submitting claims.
- 87650 — Infectious agent detection by nucleic acid; Streptococcus, group A, direct probe technique.
- 87651 — Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe technique.
- 87652 — Infectious agent detection by nucleic acid; Streptococcus, group A, quantification.
- 87880 — Infectious agent antigen detection by immunoassay; Streptococcus, group A (RADT).
- 87081 — Culture, presumptive, pathogenic organisms, screening only (throat culture).
Provider action — avoid molecular strep testing for coverage (policy highlight)
Do not order rapid molecular (NAAT/amplified probe) tests for suspected strep throat for coverage purposes — these assays are considered investigational and not medically necessary under this policy; documentation of clinical rationale will not change the noncoverage determination.
- Molecular platforms (e.g., FDA-cleared Alere i Strep A 2, Xpert Xpress Strep A) and assignment of CPT codes do not establish medical necessity.
- Policy does not identify any covered indications for molecular Group A Streptococcus tests.
Billing Codes
| 87650 | Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, direct probe technique. |
| 87651 | Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, amplified probe technique. |
| 87652 | Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, quantification. |
| 87880 | Infectious agent antigen detection by immunoassay with direct optical observation; Streptococcus, group A. |
| 87081 | Culture, presumptive, pathogenic organisms, screening only. |
Definitions
Clinical Background
Group A Streptococcus (Streptococcus pyogenes) is a common bacterial cause of acute pharyngitis. Rapid molecular assays detect organism-specific nucleic acid from throat swab specimens using methods such as polymerase chain reaction or other nucleic acid amplification techniques. Although these assays offer faster results than culture and higher analytic sensitivity than rapid antigen detection tests, detection of nucleic acid alone does not by itself establish that current symptoms are due to active infection. Based on available evidence, rapid molecular tests for Group A Streptococcus are considered investigational and not medically necessary for suspected streptococcal pharyngitis.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.